In this study, the use of a cohort of 38 T-ALL with mature survival data has allowed us to reveal that patients with high NFE2L2 expression and signal activation presented a significantly reduced disease-free survival compared to those with low NFE2L2 expression and signalling. This evidence concerns the gene NFE2L2 and acute lymphoblastic leukemia.